In the first three months of 2023 Krka Group revenue amounted to €458.2 million, which is a 6% increase year on year. This resulted in €89.0 million of net profit, a 2% decrease year on year. The Krka Supervisory Board discussed the First Quarter 2023 interim report for the Krka Group and Krka, d. d. at its regular meeting yesterday.
President of the Management Board and Chief Executive Jože Colaric explained: "The Krka Group operating results for the first quarter are good. Sales increased in five sales regions and in most of our key markets. Earnings before interest and taxes have remained high. Net profit is slightly lower compared to the first quarter last year, a result of increased foreign exchange losses and higher income tax. Over the reporting period we obtained marketing authorisations for three new medicinal products, and devoted €21.8 million to investments - primarily to support our production, research and development activities. Krka has been generating a robust cash flow from operating activities, which provides a stable source for financing our operating liabilities and investments, and for pursuing the company's long-term dividend policy. The Supervisory Board and Management Board have thus proposed that Krka shareholders receive a dividend for 2022 in the amount of €6.60 gross per share. This is an increase by 17.2% from last year. Shareholders will vote on this proposal at the 29th AGM on July 6."
Contact
Krka, d. d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia
Phone: (+386) 7 331 21 11
Fax: (+386) 7 332 15 37
Email: info@krka.biz
President of the Management Board and Chief Executive Jože Colaric explained: "The Krka Group operating results for the first quarter are good. Sales increased in five sales regions and in most of our key markets. Earnings before interest and taxes have remained high. Net profit is slightly lower compared to the first quarter last year, a result of increased foreign exchange losses and higher income tax. Over the reporting period we obtained marketing authorisations for three new medicinal products, and devoted €21.8 million to investments - primarily to support our production, research and development activities. Krka has been generating a robust cash flow from operating activities, which provides a stable source for financing our operating liabilities and investments, and for pursuing the company's long-term dividend policy. The Supervisory Board and Management Board have thus proposed that Krka shareholders receive a dividend for 2022 in the amount of €6.60 gross per share. This is an increase by 17.2% from last year. Shareholders will vote on this proposal at the 29th AGM on July 6."
Contact
Krka, d. d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia
Phone: (+386) 7 331 21 11
Fax: (+386) 7 332 15 37
Email: info@krka.biz
© 2023 Business Wire